Recent Updates
Recently added Catalysts
REPL Negative Sentiment Score: 30/100

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

Key Takeaway: Replimune Group, Inc. is currently facing a class action lawsuit initiated by The Gross Law Firm. The lawsuit alleges that during the class period from November 22, 2024, to July 21, 2025, the company misrepresented the prospects of the IGNYTE trial. As a result, the FDA has classified the trial as inadequate. Shareholders are encouraged to register for the lawsuit by September 22, 2025, to potentially serve as lead plaintiffs.

Market Sentiment Analysis

CONCERNS & RISKS

  • The IGNYTE trial's prospects were overstated, affecting investor confidence.
  • The FDA deemed the IGNYTE trial inadequate and not well-controlled.
  • Allegations indicate a lack of transparency about the company's operational issues.

Full Press Release Details

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 22, 2024 to July 21, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: September 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=166120&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of REPL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 22, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Replimune Group shareholders?

The class period for shareholders is from November 22, 2024, to July 21, 2025.

What allegations are made against Replimune Group?

The allegations include falsely overstating the IGNYTE trial's prospects, resulting in FDA concerns.

What is the lead plaintiff appointment deadline?

The deadline to seek lead plaintiff status is September 22, 2025.

How can shareholders participate in the class action?

Shareholders can register for the class action via the provided link to monitor updates.

Why choose Gross Law Firm for this case?

Gross Law Firm focuses on protecting investors' rights against fraud and misleading practices.

Last updated: Sep 10, 2025